Navigation Links
Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting

JERUSALEM, Israel, November 6, 2012 Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012. QNASL is a recently approved "dry" nasal aerosol corticosteroid that treats seasonal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

Findings from one clinical study being presented at the meeting highlight the nasal symptom improvement and efficacy profile of QNASL in children ages 6-11 with seasonal allergic rhinitis (SAR), while others reinforce ocular safety, appropriate dosing and device performance.

On March 23, 2012, the U.S. Food and Drug Administration (FDA) approved QNASL. The product became available to patients by prescription in April 2012, making it the first marketed nonaqeous or "dry" nasal aerosol product in a category that reports annual sales of $2.5 billion. QNASL is delivered as a once-daily, nonaqueous aerosol that uses an environmentally friendly propellant (HFA) and contains a built-in dose counter.

"QNASL has provided an alternative therapy for patients suffering from allergic rhinitis," said Dr. William Storms, MD, practicing allergist, clinical professor at the University of Colorado Health Sciences Center and founder of the William Storms Allergy Clinic in Colorado Springs, CO. "The dry mode of delivery of QNASL, along with the performance and functionality of the device, offers patients a safe and effective way to manage and control their nasal allergy symptoms. The data to be presented at ACAAI this year further demonstrate the efficacy profile of QNASL, especially among the pediatric population and confirm the product's ocular safety profile in adolescents and adults."

The following QNASL (beclomethasone dipropionate) data will be presented during poster sessions on Saturday, November 10 from 12:30 1:30 p.m. PST and Sunday, November 11 from 12:00 1:00 p.m. PST in Hall C (first floor) of the Anaheim Convention Center at the ACAAI Annual Meeting:

  • #P314: Device and Integrated Dose Counter Performance of Beclomethasone Dipropionate Nasal Aerosol During Daily Use

  • #P329: Nasal Symptom Improvement Following Once-Daily Treatment With Beclomethasone Dipropionate Nasal Aerosol (80 g or 160 g) in Children With Seasonal Allergic Rhinitis

  • #P330: Efficacy, Safety, and Optimal Dose Selection of Beclomethasone Dipropionate Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

  • #P331: Evaluation of Ocular Safety Following Long-Term Treatment With Beclomethasone Dipropionate Nasal Aerosol in Subjects With Perennial Allergic Rhinitis

  • #P325: Nasal Deposition of Beclomethasone Dipropionate Nasal Aerosol Versus Fluticasone Propionate and Mometasone Furoate Aqueous Nasal Sprays

"The data to be presented at ACAAI provide additional evidence that QNASL is a generally well-tolerated and effective treatment option for people suffering with seasonal and year-round nasal allergies," said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. "We are committed to the development of novel therapies to help the millions of Americans who suffer from allergic rhinitis effectively manage and control their burdensome symptoms."

Contact: Denise Bradley
Teva North America


Related medicine news :

1. Medical care presents update on pharmaceutical health services research
2. Results of the STEMI-RADIAL trial presented at TCT 2012
3. Philippe Généreux, MD, presented with 2012 TCT Young Investigator Award
4. Results of the XIMA trial presented at TCT 2012
5. Barry D. Rutherford, M.D. presented with Master Clinical Operator Award at TCT 2012
6. Renu Virmani, M.D. presented with 2012 TCT Career Achievement Award
7. Results of the AIDA STEMI MRI sub-study presented at TCT 2012
8. Results of the PC trial presented at TCT 2012
9. Results of the POSEIDON trial presented at TCT 2012
10. 1-year results of ADAPT-DES presented at TCT 2012
11. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology: